menu search

ROIV / Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth
Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter financial results that fell short of expectations for both earnings and sales.   For the three months ended June 30, 2023, the company reported a loss per share of $0.38, $0.10 lower than the Street estimate of a loss per share of $0.28. Read More
Posted: Aug 14 2023, 10:47
Author Name: Proactive Investors
Views: 121354

ROIV News  

Roivant Sciences: Risk-Transforming Deal Met With Crickets

By Seeking Alpha
October 24, 2023

Roivant Sciences: Risk-Transforming Deal Met With Crickets

Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a more_horizontal

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?

By Zacks Investment Research
September 27, 2023

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. more_horizontal

Roivant stock could go higher on monetization potential of ‘blockbuster' assets

By Proactive Investors
September 26, 2023

Roivant stock could go higher on monetization potential of ‘blockbuster' assets

Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-s more_horizontal

Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?

By Invezz
September 9, 2023

Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?

Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company's future. The shares surged more_horizontal

Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, more_horizontal

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

By Proactive Investors
August 14, 2023

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter f more_horizontal

2 Magnificient Growth Stocks I'm Buying in August

By The Motley Fool
August 2, 2023

2 Magnificient Growth Stocks I'm Buying in August

Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant invest more_horizontal

Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche

By Zacks Investment Research
July 14, 2023

Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche

Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's infl more_horizontal


Search within

Pages Search Results: